Lasmiditan Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg, 100 mg, 200 mg
Reference Brands: Reyvow (USA)
Category:
Neurology
Lasmiditan is available in Tablets
and strengths such as 50 mg, 100 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lasmiditan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lasmiditan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lasmiditan is an oral medication used for the acute treatment of migraine attacks and is marketed under the brand name Reyvow. It is indicated for adults experiencing migraine with or without aura, providing rapid relief from headache pain and associated migraine symptoms. Lasmiditan is not used for migraine prevention and is intended solely for treatment at the onset of a migraine attack.
As a selective serotonin 5-HT<sub>1F</sub> receptor agonist, lasmiditan works by modulating specific pathways in the central nervous system involved in migraine pain without causing blood vessel constriction. This makes it a suitable option for patients who have cardiovascular risk factors and cannot take traditional triptan medications. Taken orally, lasmiditan provides a convenient and targeted approach for controlling migraine episodes, helping to reduce pain, sensory disturbances, and other migraine-related symptoms under medical supervision.
It represents an important addition to acute migraine therapy, offering relief through a mechanism distinct from vasoconstrictive migraine medications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing